Endo International (NASDAQ:ENDP) (TSE:ENL) issued an update on its FY 2021 earnings guidance on Thursday morning. The company provided EPS guidance of $2.800-$2.850 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.330. The company issued revenue guidance of $2.90 billion-$2.94 billion, compared to the consensus revenue estimate of $2.79 billion.
Shares of NASDAQ:ENDP traded down $0.06 on Thursday, hitting $6.05. The company’s stock had a trading volume of 3,065,905 shares, compared to its average volume of 6,679,024. The company has a 50-day simple moving average of $4.63 and a 200 day simple moving average of $4.46. Endo International has a 1 year low of $1.94 and a 1 year high of $10.89. The company has a market capitalization of $1.41 billion, a PE ratio of 21.61 and a beta of 1.21.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Thursday, November 4th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.34. The firm had revenue of $772.03 million for the quarter, compared to analysts’ expectations of $667.94 million. Endo International had a negative return on equity of 108.42% and a net margin of 2.30%. The company’s revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.52 EPS. Sell-side analysts anticipate that Endo International will post 2.84 earnings per share for the current year.
An institutional investor recently raised its position in Endo International stock. Bank of New York Mellon Corp increased its stake in shares of Endo International plc (NASDAQ:ENDP) (TSE:ENL) by 4.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,163,896 shares of the company’s stock after acquiring an additional 97,708 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.93% of Endo International worth $7,012,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 79.45% of the stock is owned by hedge funds and other institutional investors.
About Endo International
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals.
Featured Story: Quick Ratio
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.